Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17.
Patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis benefit from referral to subspecialty care. While several clinical prediction rules exist to identify advanced fibrosis, the cutoff for excluding cirrhosis due to NAFLD is unclear. This analysis compared clinical prediction rules for excluding biopsy-proven cirrhosis in NAFLD.
Adult patients were enrolled in the NASH Clinical Research Network (US) and the Newcastle Cohort (UK). Clinical and laboratory data were collected at enrolment, and a liver biopsy was taken within 1 year of enrolment. Optimal cutoffs for each score (eg, FIB-4) to exclude cirrhosis were derived from the US cohort, and sensitivity, specificity, positive predictive value, negative predictive value and AUROC were calculated. The cutoffs were evaluated in the UK cohort.
147/1483 (10%) patients in the US cohort had cirrhosis. All prediction rules had similarly high NPV (0.95-0.97). FIB-4 and NAFLD fibrosis scores were the most accurate in characterising patients as having cirrhosis (AUROC 0.84-0.86). 59/494 (12%) patients in the UK cohort had cirrhosis. Prediction rules had high NPV (0.92-0.96), and FIB-4 and NAFLD fibrosis score the most accurate in the prediction of cirrhosis in the UK cohort (AUROC 0.87-0.89).
This cross-sectional analysis of large, multicentre international datasets shows that current clinical prediction rules perform well in excluding cirrhosis with appropriately chosen cutoffs. These clinical prediction rules can be used in primary care to identify patients, particularly those who are white, female, and <65, unlikely to have cirrhosis so higher-risk patients maintain access to specialty care.
非酒精性脂肪性肝病 (NAFLD) 肝硬化患者受益于转至亚专科治疗。虽然有几种临床预测模型可用于识别晚期纤维化,但排除因 NAFLD 引起的肝硬化的截止值尚不清楚。本分析比较了排除 NAFLD 活检证实肝硬化的临床预测模型。
成年患者在美国 NASH 临床研究网络 (US) 和纽卡斯尔队列 (UK) 中入组。在入组时收集临床和实验室数据,并在入组后 1 年内进行肝活检。从 US 队列中得出每个评分(例如 FIB-4)的最佳截止值以排除肝硬化,并计算敏感性、特异性、阳性预测值、阴性预测值和 AUROC。在 UK 队列中评估这些截止值。
US 队列中 147/1483 (10%)患者患有肝硬化。所有预测模型的 NPV 均相似高(0.95-0.97)。FIB-4 和 NAFLD 纤维化评分最准确地将患者归类为患有肝硬化(AUROC 0.84-0.86)。UK 队列中 59/494 (12%)患者患有肝硬化。预测模型具有高 NPV(0.92-0.96),FIB-4 和 NAFLD 纤维化评分在 UK 队列中对肝硬化的预测最准确(AUROC 0.87-0.89)。
本研究对来自多个国际大型中心的横断面数据集进行了分析,结果表明,目前的临床预测模型在使用适当的截止值排除肝硬化时表现良好。这些临床预测模型可用于初级保健,以识别患者,特别是那些白人、女性和 <65 岁的患者,他们不太可能患有肝硬化,从而使高危患者能够继续获得专科治疗。